Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) research hub

A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)

This study is looking at a new treatment combination for certain advanced cancers, including lung, head and neck, and bladder cancer. Researchers want to see if combining two new drugs with an existing one, Pembrolizumab, can help shrink tumours and is safe for patients.